Best of ASCO 2022 —bladder cancer

SummaryAlthough no game-changing studies in bladder cancer were presented this year at ASCO, we saw a  series of interesting data including follow-up updates, exploratory analyses and promising results of phase I/II trials. An up-date analysis of the JAVELIN 100 Bladder study indicated a benefit of avelumab maintenance treatment irrespective of the response to platin-based first-line treatment an d administration of second-line treatment. A new HER2-directed antibody drug conjugate, disitamab vedotin, showed promising results with high-response rates in HER2 high and low bladder cancer. Longer follow-up data confirmed the significant benefit of enfortumab-vedotin in the third-line treatment setting.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research